값Q4, 25TTM판매비·일반관리비——연구개발——영업 이익-433 K—비영업 수익, 합계——이자비용(자본화한 이자 차감 후)——이자비용을 제외한 비영업 수익——비정상 수입/지출——세전소득-659.85 M—지분법 손익——세금1.86 M—비지배 지분——세후 기타 수익/비용——중단된 사업 부문 제외 순이익-661.71 M—중단된 사업——순이익-661.71 M—희석보정——우선배당——보통주주에게 귀속되는 희석 순이익-661.71 M—주당 순이익(기본 EPS)——희석 주당 순이익 (희석 EPS)-2.92—평균 발행주식수226.53 M—희석주식수226.53 M—EBITDA——EBIT——매출원가——기타 매출원가——감가상각 및 무형자산 상각 (현금흐름)400 K—
AtaiBeckley Inc
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.